|
Brook Byers is Chairman of the Board of Directors of the OptiMedica� Corporation. He has been closely involved with more than 40 new technology ventures. In 1984, he formed the first Life Sciences venture capital group and led Kleiner, Perkins, Caufield & Byers (KPCB) to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 90 Life Sciences companies which have developed hundreds of products to treat major underserved medical needs.
Mr. Byers is currently on the Board of Directors of eight additional companies, including CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, Nanofluidics and XDx, Inc.. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Ligand Pharmaceuticals (Chairman), Hybritech (Chairman), Genprobe, Nanogen, and others. These companies have pioneered the medical uses of molecular biology, monoclonal antibodies, molecular diagnostics and genomics.
Mr. Byers is currently a Board member of the University of California at San Francisco Medical Foundation, the California Healthcare Institute, the New Schools Foundation, Stanford's Bio-X Advisory Council, the Stanford Eye Council, and TechNet. He is Co-Chair of the current five year, $1.4 billion, UCSF Capital Campaign and was formerly a Director of the Entrepreneurs Foundation, the Asian Art Museum in San Francisco, the Stanford Graduate School of Business Advisory Council, That Man May See (UCSF) Vision Research Foundation (Chairman), and the Georgia Tech Advisory Board. Raised in Atlanta, Georgia, Brook graduated with a B.S.E.E. from Georgia Tech and an M.B.A. from Stanford. | 